AtaGenix

Hot search： CD47 │ IL6 │ PD-L1 │ CTLA-4 │ TIGIT
Current Site： Product Center / Recombinant Protein / Drug Targets / Recombinant Human CD28 protein ,C- Fc Tag

Recombinant Human CD28 protein ,C- Fc Tag

  • 1
ATMP00032HU
-
+
Spot
Inquiry
  • Product Details
  • Frontier progress
  • How to order
  • Instructions
Summaryicon
English name
Recombinant Human CD28 protein ,C- Fc Tag
Purity
>90% as determined by SDS-PAGE
Endotoxin level
<1.0 EU per μg of the protein as determined by the LAL method.
Construction
A DNA sequence encoding the human CD28(Met1~Pro152) was fused with the C-terminal Fc Tag
Accession #
P10747
Host
Mammalian cells
Species
Homo sapiens (Human)
Predicted Molecular Mass
42.63KDa
Formulation
Supplied as solution form in PBS, pH7.5 or lyophilized from PBS, pH7.5.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability &Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
SDS-PAGE imageicon
    Backgroundicon
    Background
    T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells.
    Alternative Names
    CD28,Tp44
    References
    Zhao, Yang, Zhang, Lu, Xiong, Zhang, Zhou, Qi, He, Ding, Hu, De Smet, Lu, Huang (2020) Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia Molecular therapy oncolytics 18() 272-281
    CD19-directed chimeric antigen receptor-T (CAR-T) cells with a 4-1BB or CD28 co-stimulatory domain have shown impressive antitumor activity against relapsed or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). However, a parallel comparison of their performances in r/r B-ALL therapy has not been sufficiently reported. Here, we manufactured 4-1BB- and CD28-based CD19 CAR-T cells using the same process technology and evaluated their efficacy and safety in r/r B-ALL therapy based on pre-clinical and exploratory clinical investigations. In B-ALL-bearing mice, a similar antitumor effect and CAR-T kinetics in peripheral blood were observed at the CAR-T dose of 1 × 107/mouse. However, when the dose was decreased to 1 × 106/mouse, 4-1BB CAR-T cells were more potent in eradicating tumor cells and showed longer persistence than CD28 CAR-T cells. Retrospective analysis of an exploratory clinical study that used 4-1BB- or CD28-based CAR-T cells to treat r/r B-ALL was performed. Compared with CD28 CAR-T cells, 4-1BB CAR-T cells resulted in higher antitumor efficacy and less severe adverse events. This study demonstrated that the performance of 4-1BB CAR-T cells was superior to that of CD28 CAR-T cells in suppressing CD19+ B-ALL, at least under our manufacturing process.

    Guarantee and Disclaimer:

    After receiving the product, if finds that the product is mismatched, damaged or missing components, please keep the original package and submit the objection to the company by mail within seven working days. Failure to file an objection within the time limit is considered qualified.

    When the buyer keeps the product, it should be kept in accordance with the storage conditions shown in the product label and the manual. If the product quality is caused by improper storage, it will not be guaranteed.

    When the buyer tests the product, they should be submitted by the beginning of use when found the quality issue, rather than when the product was used or used up, in order to prepare our products for recycling and confirm the quality of the products. If it is the quality problem, our company is responsible for exchange or return. In the event of a claim, our company will compensate the discretion within the scope of the product price limit and will not accept any part of the value of the product itself. Since the date of receipt, the product has not been reflected for more than three months and should not be returned.

    The products provided by our company are for research use only and should not be used for clinical diagnosis or treatment. If a unit or individual changes the use of our products without authorization, we will not bear any responsibility.

    AtaGenix
    Copyright © 2024 Lawyer Theme All Rights Reserved
    Site map | Contact us | Join us